Our results, combined with the abovementioned references (32–35), may suggest that: 1) high IL-6Ra levels favor JAK/STAT pathway activation and the oncoinflammatory state in ET patients; 2) high M-CSF levels favor tissue homeostasis and attenuate inflammation in BM from CALR+ patients. The gene discussed is CALR; the disease is essential thrombocythemia.